Table 2.
Patient Characteristics
| No. of Patients (%) | |
|---|---|
| Male gender | 8 (53) |
| Median age (range) | 59 (36–67) |
| White race | 12 (80) |
| Median creatinine clearance, mL/minute (range) | 42.8 (29–60) |
| CKD staging | |
| Stage 2 | 1 (7) |
| Stage 3 | 13 (87) |
| Stage 4 | 1 (7) |
| Stage 5 | 0 |
| Durie-Salmon staging | |
| Stage III B | 8 (53) |
| Stage III A | 0 |
| Stage III, creatinine at the time of diagnosis not available | 4 (27) |
| Stage II B | 3 (20) |
| Isotypes | |
| IgG kappa | 5 (33) |
| IgG lambda | 3 (20) |
| IgA kappa | 2 (13) |
| IgD lambda | 1 (7) |
| Kappa light chain | 3 (20) |
| Lambda light chain | 1 (7) |
| Previous treatment regimen | |
| One regimen | 5 (33) |
| Two regimen | 10 (67) |
| Previous BMT | 2 (13) |
| Karnofsky Performance Score | |
| 70 | 1 (7) |
| 80 | 7 (47) |
| 90 | 7 (47) |
| Disease status at the time of transplantation | |
| VGPR | 3 (20) |
| PD | 5 (33) |
| CR | 4 (27) |
| PR | 3 (20) |
| SD | 0 |
| Days in the hospital (range) | 16 (12–74) |
| Median follow-up in months for those who were alive at day 100 (range) | 16.5 (3–44) |
CKD indicates chronic kidney disease; BMT, bone marrow transplant; VGPR, very good partial response; PD, progressive disease; CR, complete response; PR, partial response; SD, stable disease.
A <50 % reduction in serum M-protein, or if the patient has light chain disease only, a <50% reduction in the urine M-protein (Bence Jones Protein).